Methods and compositions useful for inhibition of angiogenesis
AssigneeThe Scripps Research Institute
InventorsPeter Brooks, David A. Cheresh
Life of this patent
Estimating the term…
Abstract
The present invention describes methods for inhibition of angiogenesis in tissues using vitronectin .alpha..sub.v .beta..sub.3 antagonists, and particularly for inhibiting angiogenesis in inflamed tissues and in tumor tissues and metastases using therapeutic compositions containing anti-.alpha..sub.v .beta..sub.3 monoclonal antibodies.
Claims41
A method for inhibiting angiogenesis in a solid tumor in a patient wherein cells of the tumor do not express levels of integrin .alpha..sub.v .beta..sub.3 detectable by immunohistochemistry comprising administering to said patient a composition comprising an angiogenesis-inhibiting amount of an anti-.alpha..sub.v .beta..sub.3 monoclonal antibody, whereby integrin .alpha..sub.v .beta..sub.3 expressed on the surface of vascular endothelial cells involved in said angiogenesis is contacted by said antibody resulting in inhibition in the blood supply to the tissue of said solid tumor.
A method for inhibiting angiogenesis in a solid tumor in a patient wherein cells of the tumor do not express levels of integrin .alpha..sub.v .beta..sub.3 detectable by immunohistochemistry with monoclonal antibody LM609 having ATCC accession number HB9537, comprising administering to said patient a composition comprising an angiogenesis-inhibiting amount of anti-.alpha..sub.v .beta..sub.3 monoclonal antibody, whereby integrin .alpha..sub.v .beta..sub.3 expressed on the surface of vascular endothelial cells involved in said angiogenesis is contacted by said antibody resulting in inhibition in the blood supply to the tissue of said solid tumor.
A method for inhibiting angiogenesis in an inflamed, angiogenic tissue of a patient, comprising administering to said patient a composition comprising an angiogenesis-inhibiting amount of an anti-.alpha..sub.v .beta..sub.3 monoclonal antibody, whereby integrin .alpha..sub.v .beta..sub.3 expressed on the surface of vascular endothelial cells involved in said angiogenesis in said angiogenic tissue is contacted by said antibody resulting in inhibition in the blood supply to said angiogenic tissue.
Dependencies are inferred from the claim text.